GALT
- Galectin Therapeutics Inc.
()
Overview
Company Summary
Galectin Therapeutics Inc. (GALT) is a biotechnology company that focuses on the development of therapies for fibrotic diseases and cancer. The company specializes in targeting galectin proteins, which are involved in various biological processes.
Galectin Therapeutics is primarily known for its lead drug candidate, GR-MD-02. This investigational therapy is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a severe form of fatty liver disease with potential systemic manifestations. GR-MD-02 works by modulating the galectin protein to reduce inflammation and fibrosis in the liver, which are key factors in the progression of NASH.
Aside from NASH, Galectin Therapeutics is also exploring the potential of its galectin-targeting approach in other fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and kidney fibrosis. The company's pipeline includes other drug candidates that aim to address these conditions.
In addition to fibrotic diseases, Galectin Therapeutics is involved in the development of galectin-targeted immunotherapy for the treatment of various types of cancers. By harnessing the immune system's ability to recognize and attack cancer cells, the company aims to develop innovative and effective treatments that could potentially improve patient outcomes.
Overall, Galectin Therapeutics Inc. focuses on utilizing its expertise in galectin protein modulation to develop therapeutic solutions for fibrotic diseases, including NASH, as well as exploring applications in cancer immunotherapy.